

10/749,932

STN-structure Search  
1.20.05

=> d ibib abs hitstr 1-3

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2004:565121 CAPLUS  
DOCUMENT NUMBER: 141:111586  
TITLE: Compositions of benzoquinolizinecarboxylic acid drugs  
and use for treatment or prevention of infective  
disease  
INVENTOR(S): Saoji, Dilip G.; Nagori, Rajendra N.; Shetty, Nitin;  
Shukla, Milind C.; De, Souza, Noel J.  
PATENT ASSIGNEE(S): India  
SOURCE: PCT Int. Appl., 43 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058303	A2	20040715	WO 2003-IN423	20031231
WO 2004058303	A3	20040826		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004176321	A1	20040909	US 2003-749931	20031231
PRIORITY APPLN. INFO.:			IN 2002-MU1169	A 20021231

OTHER SOURCE(S): MARPAT 141:111586

AB The present invention relates to a pharmaceutical composition in aqueous solution form  
useful for parenteral application to a subject for treatment or prevention of an infective disease. In particular the present invention relates to such a composition having as an active agent, e.g.,

S-(-)-9-fluoro-6,7-dihydro-  
8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid or S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid arginine salt (I) or a benzoquinolizine-2-carboxylic acid. Thus, a solution contained I 0.9 and L-arginine 0.30 g, and water for injection qs to 100 mL.


IT 124858-35-1 154357-42-3 160961-35-3  
306302-57-8 306748-89-0 373603-21-5  
373603-35-1 373603-36-2 373603-41-9  
396132-50-6 627891-20-7 720684-21-9  
720684-22-0 720684-26-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(comps. of benzoquinolizinecarboxylic acid drugs for treatment or prevention of infective disease)

RN 124858-35-1 CAPLUS

CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo- (9CI) (CA INDEX NAME)


10/749,932



RN 154357-42-3 CAPLUS

CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 160961-35-3 CAPLUS

CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 306302-57-8 CAPLUS

CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, hydrate (5:1), (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

10/749,932




● 1/5 H<sub>2</sub>O

RN 306748-89-0 CAPLUS  
CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3  
CMF C19 H21 F N2 O4


Absolute stereochemistry. Rotation (-).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 373603-21-5 CAPLUS  
CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-3-methyl-1-piperidinyl)-5-methyl-1-oxo-, (5S)- (9CI) (CA INDEX

10/749,932


CRN 124858-35-1  
CMF C19 H21 F N2 O4




CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 720684-21-9 CAPLUS  
CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, hydrate (5:1) (9CI) (CA INDEX NAME)




●1/5 H<sub>2</sub>O

RN 720684-22-0 CAPLUS  
CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, hydrate (5:1), (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

10/749,932




● 1/5 H<sub>2</sub>O

RN 720684-26-4 CAPLUS

CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny)-5-methyl-1-oxo-, monosodium salt, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● Na

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:565095 CAPLUS

DOCUMENT NUMBER: 141:111581

TITLE: Benzoquinolizine-2-carboxylic acid-containing compositions

INVENTOR(S): Saoji, Dilip G.; Nagori, Rajendra N.; Shukla, Milind C.; Bhagwat, Sachin S.; Gupte, Shrikant V.; Patel, Mahesh V.; Jha, Rasendrakumar; Kukreja, Anil; De Souza, Noel J.

PATENT ASSIGNEE(S): India

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058262	A1	20040715	WO 2003-IN422	20031231

10/749,932

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004176337 A1 20040909 US 2003-749933 20031231

PRIORITY APPLN. INFO.: IN 2002-MU1170 A 20021231

OTHER SOURCE(S): MARPAT 141:111581


AB The invention relates to topical compns. of an antibacterial benzoquinolizine-2-carboxylic acid, incorporated either as the single therapeutic ingredient in hitherto undescribed pharmaceutical compns., or as an ingredient in novel combination with at least one agent selected from a retinoid, an antifungal agent, another antibacterial compound and/or a steroidal/nonsteroidal anti-inflammatory agent. Processes for preparation of the compns., the use of the compns. and a method of therapeutic or prophylactic use of such a composition for the treatment of dermal, ophthalmic, otic and nasal infections, with or without attendant inflammation are disclosed. Thus, a gel contained RS-(+)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid 1.00, Carbopol 1.20, NaOH 0.112, diethanolamine 0.36, disodium edetate 0.10, sodium sulfite 0.05, and water qs to 100%.

IT 124858-35-1 154357-42-3 160961-35-3  
306302-57-8 306748-89-0 373603-21-5  
373603-35-1 373603-36-2 373603-41-9  
396132-50-6 627891-20-7 720684-21-9  
720684-22-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(benzoquinolizinecarboxylic acid-containing topical compns.)

RN 124858-35-1 CAPLUS

CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo- (9CI) (CA INDEX NAME)




RN 154357-42-3 CAPLUS

CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/749,932

Absolute stereochemistry.



RN 720684-21-9 CAPLUS

CN 1H,5H-Benzo[*ij*]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, hydrate (5:1) (9CI) (CA INDEX NAME)




● 1/5 H<sub>2</sub>O

RN 720684-22-0 CAPLUS

CN 1H,5H-Benzo[*ij*]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, hydrate (5:1), (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● 1/5 H<sub>2</sub>O

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:950059 CAPLUS

DOCUMENT NUMBER: 140:8806

TITLE: Preparation of crystalline fluoroquinolone arginine salts for pharmaceuticals

10/749,932

INVENTOR(S): De Souza, Noel J.; Deshpande, Prasad K.; Shukla, Milind C.; Jaweed, Mukarram Siddiqui M.; Kulkarni, Dilip Ganesh; Rahman, Ansari Azizur; Yeole, Ravindra D.; Patel, Mahesh V.; Gupte, Shrikant V.  
PATENT ASSIGNEE(S): Wockhardt Limited, India  
SOURCE: U.S. Pat. Appl. Publ., 15 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2003225119	A1	20031204	US 2002-156685	20020528
US 6664267	B2	20031216		
US 2004063948	A1	20040401	US 2003-671040	20030925
PRIORITY APPLN. INFO.:			US 2002-156685	A3 20020528

AB The invention relates to the new arginine salt forms of RS-(±)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid (I), R-(+)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their preparation and pharmaceutical formulations which comprise those arginine salt forms as the active ingredient for its use in treating microbial infections. I was suspended in acetone, and this suspension was mixed with L-arginine and water. The mixture was stirred at 55-60° to obtain a clear solution and to this solution was added activated carbon and the solution was filtered. To the filtrate was added acetone, and the reaction mixture was stirred for an addnl. for 2 h at 30-35°, and then allowed to cool to 5°. The obtained solid was filtered and washed with acetone. The wet solid was dried at 80-85° to afford the L L-arginine salt hydrate. as a cream colored powder.

IT 306302-67-0P 306302-69-2P 306748-89-0P  
371246-52-5P 396132-50-6P 627891-14-9P  
627891-18-3P 627891-20-7P 627891-23-0P  
627891-25-2P 627891-29-6P 627891-31-0P  
627891-34-3P 627891-36-5P 627891-38-7P  
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of crystalline fluoroquinolone arginine salts for pharmaceuticals)

RN 306302-67-0 CAPLUS

CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:1)  
(9CI) (CA INDEX NAME)

CM 1


CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




10/749,932




RN 154357-42-3 CAPLUS  
CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 160961-35-3 CAPLUS  
CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



=> d his

(FILE 'HOME' ENTERED AT 13:40:22 ON 20 JAN 2005)

FILE 'REGISTRY' ENTERED AT 13:41:17 ON 20 JAN 2005

L1 STRUCTURE UPLOADED

L2 4 S L1

L3 91 S L1 FULL

10/749,932


FILE 'CAPLUS' ENTERED AT 13:41:54 ON 20 JAN 2005

L4 98 S L3  
L5 94 S L-ARGININE SALT?  
L6 1 S L4 AND L5  
L7 169980 S CRYSTALLINE FORM OR POLYMORPH?  
L8 2 S L4 AND L7  
L9 3 S L6 OR L8

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> => d ibib abs hitstr 1-4

L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:565121 CAPLUS

DOCUMENT NUMBER: 141:111586

TITLE: Compositions of benzoquinolizinecarboxylic acid drugs and use for treatment or prevention of infective disease

INVENTOR(S): Saoji, Dilip G.; Nagori, Rajendra N.; Shetty, Nitin; Shukla, Milind C.; De, Souza, Noel J.

PATENT ASSIGNEE(S): India

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058303	A2	20040715	WO 2003-IN423	20031231
WO 2004058303	A3	20040826		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,


10/749,932



● 1/5 H<sub>2</sub>O

RN 720684-22-0 CAPLUS  
CN 1H,5H-Benzo[*ij*]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny)-5-methyl-1-oxo-, hydrate (5:1), (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● 1/5 H<sub>2</sub>O

L12 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2003:951022 CAPLUS  
DOCUMENT NUMBER: 140:8837  
TITLE: Preparation of crystalline fluoroquinolone arginine salt form  
INVENTOR(S): De Souza, Noel J.; Deshpande, Prasad K.; Shukla, Milind C.; Mukarram, Siddiqui M. Jaweed; Kulkarni, Dilip G.; Yeole, Ravindra D.; Patel, Mahesh V.; Gupte, Shrikant V.  
PATENT ASSIGNEE(S): Wockhardt Limited, India  
SOURCE: PCT Int. Appl., 41 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099815	A1	20031204	WO 2002-IN123	20020528

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

WO 2002-IN123

20020528

AB The invention relates to the new arginine salt forms of RS-(±)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, R-(+)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their preparation and pharmaceutical formulations which comprise those arginine salt forms as the active ingredient for its use in treating **microbial infections**. Thus, S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid (I) was treated with L-arginine in acetone solution to give the I arginine salt.

IT 306748-89-0P 627891-29-6P 627891-34-3P  
 628705-85-1P 628705-87-3P 628705-88-4P  
 628705-89-5P 628705-90-8P 628705-91-9P  
 628705-94-2P 628705-96-4P 628705-98-6P  
 628706-00-3P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of crystalline fluoroquinolone arginine salts)

RN 306748-89-0 CAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

10/749,932

Absolute stereochemistry.



RN 627891-29-6 CAPLUS


CN L-Arginine, (5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny1)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate (3:2) (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 627891-34-3 CAPLUS

CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny1)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate], monohydrate (9CI) (CA INDEX NAME)


CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4


Absolute stereochemistry. Rotation (-).

10/749,932




RN 154357-42-3 CAPLUS  
CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 160961-35-3 CAPLUS  
CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



=> d his

(FILE 'HOME' ENTERED AT 13:40:22 ON 20 JAN 2005)

FILE 'REGISTRY' ENTERED AT 13:41:17 ON 20 JAN 2005

L1 STRUCTURE UPLOADED

L2 4 S L1

L3 91 S L1 FULL

10/749,932

FILE 'CAPLUS' ENTERED AT 13:41:54 ON 20 JAN 2005

L4	98 S L3
L5	94 S L-ARGININE SALT?
L6	1 S L4 AND L5
L7	169980 S CRYSTALLINE FORM OR POLYMORPH?
L8	2 S L4 AND L7
L9	3 S L6 OR L8
L10	1653 S MICROBIAL INFECTION?
L11	2 S L4 AND L10
L12	4 S L9 OR L11

=>